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Summary
Objective: To evaluate the in-vivo therapeutic efficacy of N-iminoethyl-L-Lysine (L-NIL), a selective inhibitor of inducible nitric oxide synthase
(iNOS) in a dose response study, on the progression of lesions in the experimental osteoarthritic (OA) dog model.
Design: The sectioning of the anterior cruciate ligament of the right stifle joint of mongrel dogs was done by a stab wound. Dogs were
separated into experimental groups: Group 1 received no treatment, Groups 2, 3, and 4 received oral L-NIL (0.3, 1 or 10 mg/kg/day,
respectively) starting immediately after surgery. The OA dogs were killed at 12 weeks after surgery.
Results: Macroscopically, L-NIL decreased the size of the cartilage lesions on condyles and plateaus. The histologic severity of the cartilage
lesions was decreased in the L-NIL-treated dogs. This effect was more pronounced at the highest dosage tested (3 and 10 mg/kg/day).
Conclusions: This study confirms the effectiveness of L-NIL, a selective inhibitor of iNOS, in attenuating the progression of experimental OA.
It also clearly shows that the effect is dose-dependent.
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Osteoarthritic (OA) lesions are believed to result from an
imbalance in the anabolic and catabolic processes that
occur during the development of the disease. A decreased
synthesis of aggrecan, possibly induced by an excess
production of nitric oxide (NO), has been associated with
the catabolic events of OA.1 The nitric oxide synthase
(NOS) is responsible for the production of NO. The induc-
ible form of NOS (iNOS), which can be upregulated by
cytokines, is the main enzyme involved in the excess
production of NO in arthritic disorders.1,2 Moreover, NO can
reduce proteoglycan synthesis and enhance metallo-
protease (MMP) activity, which are likely factors contribut-
ing to cartilage damage in OA.3,4 A high level of nitrite/
nitrate has been found in the synovial fluid and serum of
patients,5 and an elevated level of iNOS synthesis/
expression in OA cartilage.6
There has been little investigation into the potential of the
NOS inhibitor on the progression of OA. We recently
conducted a study examining the in-vivo effect of L-N6-
iminoethyl-L-lysine (L-NIL), a potent and selective inhibitor
of iNOS, on the progression of experimental OA using the
anterior cruciate ligament dog model.7 This one-dose study
demonstrated that a selective inhibition of iNOS could
reduce the progression of early lesions in an experimental416OA dog model under prophylactic conditions. It was there-
fore concluded that the suppression of NO production and
the formation of peroxinitrite, a toxic, highly reactive
oxidant, may help in the preservation of cartilage.
The aim of this study was to examine, by means of a
dose-range study, the in-vivo effect of the potent NO
synthase inhibitor, L-N6-iminoethyl-L-lysine (L-NIL), on the
progression of lesions in an experimental dog model of OA
under prophylactic conditions.Materials and methodsThis research was supported in part by grants from Monsanto/
Searle U.S.A. Please address all correspondence and reprint
requests to Jean-Pierre Pelletier, MD, Unite´ de recherche en
arthrose, Centre de recherche L-C. Simard, CHUM–Campus
Notre-Dame, 1560, rue Sherbrooke Est, Montre´al (Que´bec)
H2L 4M1 Canada.EXPERIMENTAL GROUPS
Adult crossbred dogs (2–3 years old), weighing approxi-
mately 25 kg each, were used in this study. Surgical
sectioning of the ACL of the right knee was performed on
12 dogs, as previously described.8,9 Following surgery, the
dogs were kept in animal-care facilities for 1 week, then
sent to a housing farm, where they were free to exercise in
a large pen.
A total of four groups of dogs (N=3 per group) were
included in the study. Group I was operated on and
received no treatment (OA group). Groups II, III, and IV
were operated on and received L-NIL orally (0.3 mg/kg/day,
1 mg/kg/day, and 10 mg/kg/day, respectively) (Monsanto/
Searle, St Louis, MO), beginning at the time of anterior
cruciate ligament (ACL) transection of the right knee. The
four groups of operated animals were killed 12 weeks after
surgery.
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Immediately after killing, the right knees of the dogs were
dissected. Each knee was examined for gross morphologic
changes, as previously described.10 Examinations were
performed by two independent, blinded observers (JF, DJ).
The cartilage changes on the medial and lateral femoral
condyles and tibial plateaus were graded separately under
a dissecting microscope (Stereozoom: Bausch & Lomb,
Rochester, NY). The depth of erosion was graded on a
scale of 0–4.HISTOLOGIC GRADING
Histologic evaluation was performed on sagittal sections
of cartilage from the lesioned areas of each femoral con-
dyle and tibial plateau as described.8–10 Specimens were
dissected, fixed in 10% buffered formalin, and embedded in
paraffin for histologic evaluation. Serial sections (5 ì) were
stained with Safranin O. The severity of the OA lesions was
graded on a scale of 0–14, by two independent observers
(JF, DJ), using the histologic/histochemical scale of Mankin
11et al.ResultsEXPERIMENTAL ANIMALS
All dogs in each experimental group completed the
study. No sign of drug toxicity was noted in the group of
dogs treated with L-NIL. The level of daily activity was
similar in all dogs from the three experimental groups, and
there was no change in the body weight of the dogs during
the study period.MACROSCOPIC FINDINGS (TABLE I)
There was a trend in dogs treated with L-NIL for the
lesions on femoral condyles, and even more for tibial
plateaus, to be less severe in size and grade in all groups
but the 0.3 mg/kg/day one, as compared to untreated OA
group.MICROSCOPIC FINDINGS
Both for femoral condyles and tibial plateaus there was a
trend for the histologic lesions to be less severe in the
1 mg/kg/day and 10 mg/kg/day treated dogs (4.6±0.8 and
4.1±0.7) and (4.8±0.7 and 3.4±0.7), as compared to theuntreated OA group (5.0±0.6 and 5.4±0.8). These
differences did not reach statistical significance.Discussion
The results from this preliminary study demonstrate that,
in the experimental dog model of OA under prophylactic
conditions, treatment with L-NIL can, to a certain extent,
reduce the structural changes of OA, an effect that is
dose-related, with the best results achieved at the higher
dosages tested. Treatment with L-NIL reduced the progres-
sion of macroscopic cartilage lesions, both on femoral
condyles and on tibial plateaus. Again, the best results
were obtained at the higher dosages tested (1 and 10 mg/
kg/day). These differences were also observed in the
histologic study which revealed less severe lesions on the
tibial plateaus of dogs treated with the highest dosage of
L-NIL. It should be noted, however, that the differences
between the control and treatment groups did not reach
statistical significance because of the small number of
animals in each group. More precise information should be
obtained with the completion of the definite study.
This study confirms our previous study on the chondro-
protective effect of L-NIL, and clearly shows that this effect
is dose-dependent. The exact mechanism by which L-NIL
exerts this effect remains to be determined, but, as pre-
viously demonstrated, may be related to the reduced
synthesis of IL-1â and metalloproteases.Table I
Cartilage macroscopic lesions
Group* No. of
animals
Femoral Condyles Tibial Plateaus
Size
(mm2)
Grade
(0–4 scale)
Size
(mm2)
Size
(mm2)
OA (12 week) 3 17.7±7.0 1.8±0.4 30.7±5.2 2.2±0.4
L-NIL (0.3 mg/kg/day) 3 19.0±8.3 2.0±0.4 39.8±5.8 1.8±0.3
L-NIL (1 mg/kg/day) 3 14.2±8.8 1.3±0.6 32.7±7.5 2.0±0.4
L-NIL (10 mg/kg/day) 3 14.3±6.9 1.5±0.6 11.5±5.5 1.0±0.2
*Animals were killed and tissue examined at 12 weeks. L-NIL was given orally for 12 weeks beginning
immediately after surgery.Table II
Histologic-histochemical grading of cartilage lesions
Group* No. of
animals
Femoral
Condyles
Tibial
Plateaus
OA (12 week) 3 5.0±0.7 5.6±1.4
L-NIL (0.3 mg/kg/day) 3 6.8±1.0 5.5±1.4
L-NIL (1 mg/kg/day) 3 4.2±0.9 4.0±0.6
L-NIL (10 mg/kg/day) 3 4.7±0.9 3.3±0.7
*Animals were killed and tissue examined at 12 weeks. L-NIL
was given orally for 12 weeks beginning immediately after surgery.
Statistical analysis done by Mann-Whitney U-test; P-values
compared to 12 week OA group.Acknowledgments
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